Tigecycline treatment of urinary tract infection and prostatitis: case report and literature review.
作者信息
Bates Duane, Parkins Mike, Hellweg Robin, Gibson Kimberly, Bugar Jennifer M
机构信息
, BScPharm, ACPR, is the Clinical Practice Leader, Department of Pharmacy, Foothills Medical Centre, Alberta Health Services, Calgary, Alberta.
出版信息
Can J Hosp Pharm. 2012 May;65(3):209-15. doi: 10.4212/cjhp.v65i3.1144.
Abstract
摘要
相似文献
1
Tigecycline treatment of urinary tract infection and prostatitis: case report and literature review.
Can J Hosp Pharm. 2012 May;65(3):209-15. doi: 10.4212/cjhp.v65i3.1144.
2
Tigecycline treatment for urinary tract infections: case report and literature review.
J Chemother. 2011 Jun;23(3):168-70. doi: 10.1179/joc.2011.23.3.168.
3
Chronic prostatitis: management strategies.
Drugs. 2009;69(1):71-84. doi: 10.2165/00003495-200969010-00005.
4
Diagnosis and localization of a complicated urinary tract infection in neurogenic bladder disease by tubular proteinuria and serum prostate specific antigen.
Spinal Cord. 1998 Jan;36(1):33-8. doi: 10.1038/sj.sc.3100520.
5
Tigecycline in treatment of multidrug-resistant Gram-negative bacillus urinary tract infections: a systematic review.
J Antimicrob Chemother. 2014 Oct;69(10):2606-10. doi: 10.1093/jac/dku189. Epub 2014 May 30.
6
[PSA interest and prostatitis: literature review].
Prog Urol. 2013 Dec;23(16):1377-81. doi: 10.1016/j.purol.2013.05.009. Epub 2013 Jun 21.
7
Prostatitis and urinary tract infection in men: what's new; what's true?
Am J Med. 1999 Mar;106(3):327-34. doi: 10.1016/s0002-9343(99)00017-0.
8
Role of PAR2 in the Development of Lower Urinary Tract Dysfunction.
J Urol. 2016 Aug;196(2):588-98. doi: 10.1016/j.juro.2016.01.106. Epub 2016 Feb 6.
9
Current concepts in the treatment of urinary tract infections and prostatitis.
Am J Med. 1991 Dec 30;91(6A):120S-123S. doi: 10.1016/0002-9343(91)90323-p.
10
[Phytotherapy in urology. Current scientific evidence of its application in urolithiasis, chronic pelvic pain, erectile dysfunction and urinary tract infections].
Actas Urol Esp. 2013 Mar;37(3):174-80. doi: 10.1016/j.acuro.2012.07.004. Epub 2012 Oct 9.
引用本文的文献
1
Case Report: Management of recurrent UTI with tigecycline in a kidney transplant recipient.
Front Transplant. 2025 Feb 18;3:1496702. doi: 10.3389/frtra.2024.1496702. eCollection 2024.
2
Tigecycline-Based Regimens for Complicated Urinary Tract Infections Caused by Carbapenem-Resistant Gram-Negative Bacteria: Case Series.
Cureus. 2024 Jul 29;16(7):e65617. doi: 10.7759/cureus.65617. eCollection 2024 Jul.
3
Isolation and Characterization of a Novel Phage and Its Combined Effect with Tigecycline in Controlling Multidrug-Resistant -Associated Skin and Soft Tissue Infections.
Viruses. 2022 Jan 20;14(2):194. doi: 10.3390/v14020194.
4
Role of Tigecycline for the Treatment of Urinary Tract Infections.
J Pharm Technol. 2014 Jun;30(3):87-92. doi: 10.1177/8755122513519332. Epub 2014 Jan 7.
5
Efficacy and safety of tigecycline for complicated urinary tract infection: a systematic review.
Transl Androl Urol. 2021 Jan;10(1):292-299. doi: 10.21037/tau-20-959.
6
Successful Treatment of Acute Prostatitis Caused by Multidrug-Resistant With Tigecycline Monotherapy.
Open Forum Infect Dis. 2020 Jan 9;7(1):ofz551. doi: 10.1093/ofid/ofz551. eCollection 2020 Jan.
本文引用的文献
1
Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine.
Antimicrob Agents Chemother. 2011 Dec;55(12):5893-9. doi: 10.1128/AAC.00387-11. Epub 2011 Oct 3.
2
The revival of fosfomycin.
Int J Infect Dis. 2011 Nov;15(11):e732-9. doi: 10.1016/j.ijid.2011.07.007. Epub 2011 Sep 25.
3
Update in adult urinary tract infection.
Curr Infect Dis Rep. 2011 Dec;13(6):552-60. doi: 10.1007/s11908-011-0212-x.
4
Tigecycline treatment for urinary tract infections: case report and literature review.
J Chemother. 2011 Jun;23(3):168-70. doi: 10.1179/joc.2011.23.3.168.
5
Consensus review of the epidemiology and appropriate antimicrobial therapy of complicated urinary tract infections in Asia-Pacific region.
J Infect. 2011 Aug;63(2):114-23. doi: 10.1016/j.jinf.2011.05.015. Epub 2011 Jun 12.
6
Clinical experience with tigecycline as treatment for serious infections in elderly and critically ill patients.
J Microbiol Immunol Infect. 2011 Feb;44(1):45-51. doi: 10.1016/j.jmii.2011.01.009. Epub 2011 Jan 12.
7
Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa.
Mayo Clin Proc. 2011 Mar;86(3):250-9. doi: 10.4065/mcp.2010.0674.
8
Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease.
Antimicrob Agents Chemother. 2011 Mar;55(3):1162-72. doi: 10.1128/AAC.01402-10. Epub 2010 Dec 20.
9
Carbapenem versus fosfomycin tromethanol in the treatment of extended-spectrum beta-lactamase-producing Escherichia coli-related complicated lower urinary tract infection.
J Chemother. 2010 Oct;22(5):355-7. doi: 10.1179/joc.2010.22.5.355.
10
Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing.
Pharmacotherapy. 2010 Dec;30(12):1279-91. doi: 10.1592/phco.30.12.1279.
Zotero 插件